Gillison, M. L., Oliva, M., Tourneau, C. L., Saleh, R., Patnaik, A., Riess, J. W., Steeghs, N., Call, J. A., Dowlati, A., Fontana, E., Oberoi, A., Kotecki, N., Minchom, A. R., Ochsenreither, S., Ouali, K., Spreafico, A., Zivi, A., Gupta, S., Zhang, R., Nabell, L. (2025). Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6033